SCHEMBL4980070

SCHEMBL4980070

COc1cc(Nc2nc(Cl)c(F)c(N[C@@H](C)c3ccc(F)cn3)n2)n[nH]1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 14/20 0.55
JAK2 O60674 14/20 0.55
NTRK1 P04629 6/20 0.51
AURKA O14965 3/20 0.49
IGF1R P08069 2/20 0.49
GRK4 P32298 1/20 0.49
GRK5 P34947 1/20 0.49
GRK6 P43250 1/20 0.49
GRK1 Q15835 1/20 0.49
GRK7 Q8WTQ7 1/20 0.49
NTRK3 Q16288 2/20 0.49
NTRK2 Q16620 2/20 0.49
LCK P06239 2/20 0.49
RET P07949 2/20 0.49
FLT3 P36888 2/20 0.49
FYN P06241 1/20 0.49
FGFR1 P11362 1/20 0.49
FLT1 P17948 1/20 0.49
LTK P29376 1/20 0.49
KDR P35968 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL588783 0.85 JAK3 (0.57) JAK3JAK2NTRK1AURKAIGF1R
SCHEMBL3034183 0.84 NTRK1 (0.71) JAK3JAK2NTRK1AURKAIGF1R
SCHEMBL3950465 0.81 NTRK1 (0.53) JAK3JAK2NTRK1AURKAIGF1R
SCHEMBL589659 0.81 NTRK1 (0.56) JAK3JAK2NTRK1AURKAIGF1R
SCHEMBL4978955 0.79 JAK3 (0.57) JAK3JAK2NTRK1AURKAIGF1R
SCHEMBL4981488 0.77 IGF1R (0.34) JAK3JAK2NTRK1AURKAIGF1R
SCHEMBL588730 0.76 NTRK1 (0.73) JAK3JAK2NTRK1AURKAIGF1R
SCHEMBL31060183 0.76 NTRK1 (0.73) JAK3JAK2NTRK1AURKAIGF1R
SCHEMBL29434985 0.76 NTRK1 (0.73) JAK3JAK2NTRK1AURKAIGF1R
SCHEMBL18281508 0.76 NTRK1 (0.73) JAK3JAK2NTRK1AURKAIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008132502-A1 PYRAZOLYL-AMINO-SUBSTITUTED PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-11-06 WO disclosed